News

- OncoDNA Closes Successful Series B Investment Round
- Feb. 13, 2020
- read more
- OncoDNA’s personalised cancer profiling tests covered by a new insurer
- Nov. 13, 2019
- read more

- GERMLINE CANCER PREDISPOSITION: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
- Feb. 17, 2020
- read more
- LYMPHOMA: A phase 1/2 trial of anti-CD19 CAR transduced natural killer (CAR-NK) cells demonstrated efficacy in lymphoid malignancy without the CNS side-effects or production complexity of CAR-T approaches.
- Feb. 17, 2020
- read more
- COLORECTAL CANCER: A giant inflatable colon has been deployed by a team in the Lebanon to raise cancer awareness and encourage participation in screening programmes. Positive outcomes were reported.
- Feb. 17, 2020
- read more
- LUNG CANCER: Studies of patient biopsies and preclinical models imply that activating EGFR mutations drive an immunosuppressive tumour microenvironment, and suggest synergy for combination EGFR/PD-1 inhibition.
- Feb. 17, 2020
- read more
- ENDOMETRIAL CANCER: The combination of everolimus, letrozole and metformin delivered OR 28% (all PR) in pretreated patients in this small (n=54) phase II study.
- Feb. 17, 2020
- read more
- LUNG CANCER: Unsurprisingly, bronchial cells from smokers harbour more frequent mutations than non-smokers; reassuringly, quitting smoking allows replenishment of the lung epithelium by quiescent cells with lower mutational burden.
- Feb. 10, 2020
- read more
- LUNG CANCER: Screening current and former smokers by CT scanning reduced lung cancer mortality by 0.8 deaths per 1,000 person-years in a Dutch study with 10 years follow up.
- Feb. 10, 2020
- read more
- BREAST CANCER: Whilst high dose chemo with blood stem cell rescue is ineffective in advanced disease (and mired in scandal following the misconduct of Bezwoda and colleagues in the 1990's), this approach may benefit high-risk patients
- Feb. 10, 2020
- read more
- BREAST CANCER: Preclinical and patient studies have identified loss of either RB1 or PTEN as mechanisms of resistance to CDK4/6 inhibitors such as palbociclib. PTEN loss also confers resistance to PI3K inhibitors such as taselisib.
- Feb. 10, 2020
- read more
- BREAST CANCER: Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers
- Feb. 10, 2020
- read more
- BREAST CANCER: A small study identified somatic ATM mutation as a predictor of response to radiotherapy. This association is in keeping with known ATM pathway biology and warrants further study.
- Feb. 10, 2020
- read more
- DRUG TARGETS: A new front has been opened in the battle to inhibit oncogenic RAS signalling, through the use of cell-penetrating antibody technology
- Feb. 3, 2020
- read more
- CANCER AETIOLOGY: An estimated 13% of cancer globally is caused by infection, the most common agents being Helicobacter pylori, human papillomavirus and hepatitis B & C viruses
- Feb. 3, 2020
- read more
- COLORECTAL CANCER: The combination of encorafenib, binimetinib and cetuximab (triple therapy) improved survival in BRAF V600E mutant disease with manageable toxicity and minimal impact on quality of life
- Feb. 3, 2020
- read more
- PANCREATIC CANCER: The combination of cisplatin and gemcitabine with or without veliparib produced impressive response rates (65-75%) in patients with germline BRCA/PALB2 mutation
- Feb. 3, 2020
- read more
- HEPATOCELLULAR CANCER: The combination of nivolumab, ipilimumab and cabozantinib delivered an objective response rate of 31%, including complete remissions, in sorafenib-treated patients.
- Feb. 3, 2020
- read more
- IMMUNOTHERAPY Three studies have identified tumour B-cell infiltration as an independent marker of response to check-point inhibition therapy.
- Jan. 27, 2020
- read more
- BREAST CANCER: Several new anti-HER2 agents on the horizon
- Jan. 27, 2020
- read more
- LUNG CANCER: The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone
- Jan. 27, 2020
- read more
- PROSTATE CANCER: The FDA have granted priority review for the PARP inhibitor rucaparib in the mCRPC setting, based on data from the phase II TRITON2 trial which showed ORR 43.9% for BRCA1/2 mutation carriers.
- Jan. 27, 2020
- read more
- LUNG CANCER: The FDA have granted priority review for combination nivolumab/ipilimumab (anti-PD-1/CTLA-4) as first line in advanced NSCLC (EGFR/ALK wt)
- Jan. 27, 2020
- read more
- LUNG CANCER: Crizotinib delivered objective response rates of 32% in a phase I study of NSCLC harbouring MET exon 14 skipping, most of whom (62%) had received prior therapy.
- Jan. 27, 2020
- read more
- LUNG CANCER: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria
- Jan. 21, 2020
- read more
- COLORECTAL CANCER: The FDA have approved the kinase inhibitor avapritinib for patients with metastatic gastrointestinal stromal tumour (GIST) harbouring a PDGFRA exon 18 mutation
- Jan. 20, 2020
- read more
- LUNG CANCER: Correcting for tumour cellularity can improve the power of tumour mutational burden to identify immunotherapy responders
- Jan. 20, 2020
- read more
- PERSONALISED MEDICINE: In 2018, an estimated 40% of new drugs approved by the FDA were considered personalised medicines; this is expected to exceed 50% this year.
- Jan. 14, 2020
- read more
- IMMUNOTHERAPY: Meta-analysis suggests that anti-PD-1 delivers superior survival gains to anti-PD-L1. This is in keeping with current understanding of disease biology.
- Jan. 14, 2020
- read more
- DRUG TARGETS: Another VEGFR inhibitor study fails to improve overall survival despite longer progression free survival at interim analysis (ramucirumab, urothelial cancer).
- Jan. 14, 2020
- read more
- BREAST CANCER: New data from IMpassion130 confirm first interim analysis- addition of atezolizumab (aPD-L1) to nab-paclitaxel improved survival in advanced TNBC only where infiltrating immune cells express PD-L1
- Jan. 14, 2020
- read more
- BREAST CANCER Despite preclinical data identifying oncogenic RANK pathway activation, the RANK ligand inhibitor denosumab failed to improve outcomes in the neoadjuvant or adjuvant settings.
- Jan. 14, 2020
- read more
- COLORECTAL CANCER: Recent work in colorectal cancer supports a role for ctDNA methylation patterns as a tumour-specific marker.
- Jan. 6, 2020
- read more
- GERMLINE CANCER: PREDISPOSITION An international 524 family study of pathogenic PALB2 variants identified increased risk of developing breast, ovarian and pancreatic cancers.
- Jan. 6, 2020
- read more
- HEPATOCELLULAR CANCER: The FGFR4 inhibitor fisogatinib produced ORR 17% for FGF19+ tumours (IHC); responses were not seen in FGF19-negative cases. Resistance was associated with the appearance of gatekeeper mutations.
- Jan. 6, 2020
- read more
- COLORECTAL CANCER: Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
- Jan. 6, 2020
- read more
- MELANOMA: Ipilimumab (anti-CTLA-4) improved survival compared to interferon in the adjuvant setting.
- Jan. 6, 2020
- read more
- LUNG CANCER: Overweight patients achieve better responses to checkpoint inhibition.
- Jan. 6, 2020
- read more
- BREAST CANCER: Conflicting results of neoadjuvant immunotherapy for TNBC, (PD-1 inhibitor pembrolizumab vs atezolizumab)
- Dec. 30, 2019
- read more
- PANCREATIC CANCER: An FDA panel will recommend approval of olaparib as maintenance for patients with platinum sensitive/stable disease, based on data from the POLO trial.
- Dec. 30, 2019
- read more
- LUNG CANCER: The kinase inhibitor crizotinib produced ORR 27% for patients with MET exon 14 skipping or amplification in a small (n=26) early phase study
- Dec. 30, 2019
- read more
- CLINICAL TRIALS: Patients enrolled in therapeutic trials for the most common cancer types are on average 6.5 years younger than the incident population
- Dec. 30, 2019
- read more
- CANCER HETEROGENEITY: Longitudinal molecular trajectories of diffuse glioma in adults
- Dec. 23, 2019
- read more
- COLORECTAL CANCER: Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
- Dec. 23, 2019
- read more
- BREAST CANCER: ACMG have issued guidance against testing all patients with breast cancer for inherited predisposition; rather, they favour careful case-by-case assessment of risk
- Dec. 23, 2019
- read more
- BREAST CANCER: NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
- Dec. 23, 2019
- read more
- BREAST CANCER: Two new agents show promising clinical results in HER2+ disease: trastuzumab deruxtecan, an antibody-drug conjugate, and tucatinib, a small molecule inhibitor.
- Dec. 23, 2019
- read more
- Immune editing (resulting in loss of neoantigens) has been suggested as a mechanism of tumour immune escape.
- Dec. 20, 2019
- read more
- A small NCI-MATCH study of PD-1 inhibition (nivolumab) in non-CRC MSI+ tumours showed ORR 36%.
- Dec. 20, 2019
- read more
- IMMUNOTHERAPY Single agent pembrolizumab (aPD-1) failed its primary OS/PFS end-point in a phase 3 trial of previously treated hepatocellular cancer, and showed minimal activity (3-5% ORR) in treatment refractory prostate cancer.
- Dec. 20, 2019
- read more
- MELANOMA Pre-clinical work suggests potential utility of combined BRAF/MEK inhibition for BRAF wild-type, NRAS mutant melanoma.
- Dec. 20, 2019
- read more
- LYMPHOMA: Several studies from ASH reported significant activity and impressive response rates for different bispecific antibodies (mainly CD3 and CD19 or CD20).
- Dec. 16, 2019
- read more
- PANCREATIC CANCER The FDA will discuss this month an application for approval of the PARP inhibitor olaparaib as maintenance therapy for patients with BRCA-mutant cancer post upfront chemotherapy.
- Dec. 16, 2019
- read more
- CERVICAL CANCER: A vision for the global elimination of cervical cancer through systematic international vaccination programmes.
- Dec. 16, 2019
- read more
- UROTHELIAL CANCER: Pathogenic or likely pathogenic germline variants were found in 14% of patients with bladder cancer, mainly in DNA damage response genes.
- Dec. 16, 2019
- read more
- CHOLANGIOCARCINOMA The FDA have granted priority approval review of pemigatinib for patients harbouring FGFR2 fusions.
- Dec. 9, 2019
- read more
- MELANOMA Neoadjuvant administration of the oncolytic virus T-VEC improved OS in advanced melanoma.
- Dec. 9, 2019
- read more
- COLORECTAL CANCER: Integrated biomarker analysis of a large patient cohort highlights fibroblast and CD8+ lymphocyte infiltration as predictive variables.
- Dec. 9, 2019
- read more
- LUNG CANCER: New drugs targeting EGFR (lazertinib) and ALK/ROS1 (lorlatinib) have shown efficacy in phase 1/2 trials in NSCLC.
- Dec. 9, 2019
- read more
- IMPROVED SURVIVAL? The addition of VEGF inhibition to EGFR inhibition for patients with EGFR-mutant NSCLC delivered improved PFS in a phase 3 RCT...
- Dec. 9, 2019
- read more
- LUNG CANCER Patients with very high PD-L1 expression (>90%) show particularly good response to PD-1 inhibition compared to lower expressing tumours.
- Dec. 9, 2019
- read more
- HEPATOCELLULAR CANCER A novel small molecule targeting the FGF19-FGFR4 axis has entered early clinical trial in hepatic and other cancers
- Dec. 9, 2019
- read more
- VEGF as a therapeutic target The VEGF-A inhibitor bevacizumab is approved in 11 cancer types, but has failed to improve overall survival in 9 of these.
- Dec. 2, 2019
- read more
- COLORECTAL CANCER: Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- Dec. 2, 2019
- read more
- HEAD & NECK CANCER: In the phase 3 KEYNOTE-048 trial, pembrolizumab (aPD-1) plus chemotherapy was superior as first line therapy to cetuximab plus chemotherapy in patients with metastatic or locally incurable recurrent disease, regard
- Dec. 2, 2019
- read more
- CNS CANCER: Phase I clinical data from patients with low grade glioma receiving vorasidenib or vosidenib confirm early suggestions of efficacy.
- Dec. 2, 2019
- read more
- LUNG CANCER: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- Dec. 2, 2019
- read more
- IMMUNOTHERAPY: Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
- Nov. 25, 2019
- read more
- RENAL CANCER: Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
- Nov. 25, 2019
- read more
- LUNG CANCER: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
- Nov. 25, 2019
- read more
- MELANOMA: Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
- Nov. 25, 2019
- read more
- Efficacy of Pembrolizumab in Patients With Noncolorectal High MSI/Mismatch Repair–Deficient Cancer
- Nov. 18, 2019
- read more
- Glioblastoma Multiforme: 80% 6-Month Progression-Free Survival In Phase 2 Study with INO-5401 In Combination with PD-1 Inhibitor (cemiplimab)
- Nov. 18, 2019
- read more
- PROSTATE CANCER: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
- Nov. 18, 2019
- read more
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- Nov. 18, 2019
- read more
- BREAST CANCER: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
- Nov. 18, 2019
- read more
- International Alliance for Cancer Early Detection
- Nov. 12, 2019
- read more
- Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
- Nov. 12, 2019
- read more
- DCCC Danish circulating tumor DNA network (DCCC ctDNA)
- Nov. 12, 2019
- read more
- FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer
- Nov. 12, 2019
- read more
- Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program
- Nov. 12, 2019
- read more
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Nov. 12, 2019
- read more
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
- Nov. 12, 2019
- read more
- The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
- Nov. 12, 2019
- read more
- Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue
- Nov. 4, 2019
- read more
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- Nov. 4, 2019
- read more
- Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- Nov. 4, 2019
- read more
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- Nov. 4, 2019
- read more
- Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
- Nov. 4, 2019
- read more
- Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
- Nov. 4, 2019
- read more
- Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
- Nov. 4, 2019
- read more
- Three early stage clinical trials have suggested benefit of adding checkpoint inhibition to BRAF ± MEK inhibitor therapy for patients with advanced BRAF-mutant disease.
- Oct. 21, 2019
- read more
- A trial looking at avelumab and chemotherapy for bowel cancer (POLEM)
- Oct. 21, 2019
- read more
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Oct. 21, 2019
- read more
- New Studies Question Whether Novel Anti-Cancer Drugs Are Worth Their Extra Cost
- Oct. 14, 2019
- read more
- LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
- Oct. 14, 2019
- read more
- A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
- Oct. 14, 2019
- read more
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- Oct. 14, 2019
- read more
- Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
- Oct. 14, 2019
- read more
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- Oct. 14, 2019
- read more
- Breast Cancer: inactivating NF1 mutations are enriched in advanced BC and contribute to endocrine therapy resistance
- Oct. 7, 2019
- read more
- Drug targets. - Not all BRAF mutations are equal, falling into 3 different classes based on mechanism of action and therapeutic sensitivity
- Oct. 4, 2019
- read more
- Breast cancer. -Retrospective data suggest a role for mammography screening for high risk males
- Oct. 4, 2019
- read more
- Prostate cancer. -Amplification of the androgen receptor (AR) detected by ctDNA analysis is associated with poor response to anti-androgen therapy
- Oct. 4, 2019
- read more
- Lung Cancer: 3 key news from ESMO on atezolizumab (aPD-L1), Osimertinib 7 months extra survival, conflicting view on TMB
- Oct. 4, 2019
- read more
- Cholangiocarcinoma. - One third of patients with FGFR2 rearrangements showed response to targeted anti-FGFR therapy (pemigatinib) in the second line (post-chemo) setting.
- Oct. 4, 2019
- read more
- Ovarian cancer: 3 randomised controlled phase III clinical trials presented at ESMO establish the benefit of PARP inhibition ...
- Oct. 3, 2019
- read more
- OVARIAN CANCER: Maintenance therapy with the PARP inhibitor niraparib improved progression free survival; it also increased the amount of time patients were without symptoms.
- Sept. 16, 2019
- read more
- The FDA have issued a warning of rare but potentially severe lung inflammation associated with CDK4/6 inhibitor therapy (palbociclib, ibociclib, abemaciclib).
- Sept. 13, 2019
- read more
- The European Medicines Agency has followed the FDA's lead by granting tissue agnostic approval to the NTRK inhibitor larotrectinib for patients with NTRK-fusion cancers.
- Aug. 5, 2019
- read more

READ OUR FRESH

News

Key news

PRESS-RELEASE

OncoDNA Closes Successful Series B Investment Round

Feb. 13, 2020Read more

SCIENTIFIC

GERMLINE CANCER PREDISPOSITION: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Feb. 17, 2020Read more

SCIENTIFIC

LYMPHOMA: A phase 1/2 trial of anti-CD19 CAR transduced natural killer (CAR-NK) cells demonstrated efficacy in lymphoid malignancy without the CNS side-effects or production complexity of CAR-T approaches.

Feb. 17, 2020Read more

SCIENTIFIC

COLORECTAL CANCER: A giant inflatable colon has been deployed by a team in the Lebanon to raise cancer awareness and encourage participation in screening programmes. Positive outcomes were reported.

Feb. 17, 2020Read more

All news

Do you want to share some fresh news with us?